Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female infant between, and including, 8 and 12 weeks of age at the time of the first vaccination.~* Born after a gestation period of 36 to 42 weeks inclusive.~* Subjects should have received one dose of hepatitis B vaccination at birth as per local recommendations.~* Subjects who the investigator believes that their parent(s)/LAR can and will comply with the requirements of the protocol.~* Written informed consent obtained from the parent/LAR of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Administration of any vaccine since birth, with exception of HBV and Bacillus Calmette-Guérin, or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Hib, pneumococcal and/or MenC disease.~* History of seizures or progressive neurological disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* Major congenital defects or serious chronic illness.~The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:~• Current febrile illness or axillary temperature \>= 38.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- GSK2202083A + SYNFLORIX GROUP (Type: EXPERIMENTAL): Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
- INFANRIX HEXA + MENJUGATE GROUP (Type: ACTIVE_COMPARATOR): Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
- INFANRIX HEXA + SYNFLORIX GROUP (Type: ACTIVE_COMPARATOR): Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).